On Tuesday, Supernus Pharmaceuticals got a positive adjustment to its Relative Strength (RS) Rating, from 66 to 75.
How To Invest In Stocks In Both Bull And Bear Markets
This exclusive rating from Investor's Business Daily tracks price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
History shows that the stocks that go on to make the biggest gains often have an RS Rating of over 80 in the early stages of their moves. See if Supernus Pharmaceuticals can continue to show renewed price strength and hit that benchmark.
Supernus Pharmaceuticals is building a cup without handle with a 40.28 buy point. See if it can break out in heavy trading.
Supernus Pharmaceuticals posted 0% earnings growth in the latest quarterly report. Revenue gains came in at 4%. The next quarterly results are expected on or around Aug. 5.
Supernus Pharmaceuticals holds the No. 94 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Incyte and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
